{"success":true,"data":{"pressRelease":{"id":"39125","rtpr_id":"nBw5Hl87Pa","ticker":"TTRX","exchange":"NASDAQ","all_tickers":["TTRX"],"title":"Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026","author":"Business Wire","published_at":"2026-05-19T12:01:00.078Z","article_body":"Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026\n\nTurn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company\ndeveloping targeted, localized therapies for inflammatory skin diseases, today\nannounced that Bradley Burnam, Chief Executive Officer, will present at the\nJefferies Global Healthcare Conference in New York City as follows:\n\nDate: June 4, 2026\n\nTime: 9:55 AM – 10:25 AM EDT\n\nA live webcast of the presentation may be accessed on the Investors section of\nthe Turn Therapeutics website at\nhttps://ir.turntherapeutics.com/news-events/presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.turntherapeutics.com%2Fnews-events%2Fpresentations&esheet=54538125&newsitemid=20260519539083&lan=en-US&anchor=https%3A%2F%2Fir.turntherapeutics.com%2Fnews-events%2Fpresentations&index=1&md5=0200dc9e4d7d98bc973805b3993c59ca)\n. A replay of the webcast will be available on the Turn Therapeutics website\nfor approximately six months following the presentation.\n\nAbout Turn Therapeutics\n\nTurn Therapeutics is a biotechnology company focused on developing innovative,\nprecision therapies that target the underlying causes of inflammatory diseases\nwith high unmet needs. Its lead investigational therapy, GX-03, is a\nfirst-in-class, non-systemic topical inhibitor currently in development for\nthe treatment of moderate-to-severe atopic dermatitis. This therapy is\ndesigned to modulate key inflammatory pathways involved in eczema and other\ninflammatory dermatological conditions, specifically targeting IL-36 and\nIL-31, two cytokines that play distinct but interconnected roles in driving\nchronic skin inflammation and the itch-scratch cycle. GX-03 addresses IL-36\nupstream, where epithelial stress and barrier disruption initiate the\ninflammatory cascade, and IL-31 downstream, where itch signaling perpetuates\ndisease. It is currently being evaluated in a Phase 2 randomized controlled\ntrial, with topline results expected in mid-2026.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260519539083/en/\n(https://www.businesswire.com/news/home/20260519539083/en/)\n\nInvestor Relations / Media Contact \n\nSasha Damouni\n\nDamouni Group LLC\n\nSasha@damounigroup.com (mailto:Sasha@damounigroup.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5Hl87Pa","title":"Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026","author":"Business Wire","ticker":"TTRX","created":"2026-05-19T12:01:00.078Z","tickers":["TTRX"],"exchange":"NASDAQ","article_body":"Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026\n\nTurn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company\ndeveloping targeted, localized therapies for inflammatory skin diseases, today\nannounced that Bradley Burnam, Chief Executive Officer, will present at the\nJefferies Global Healthcare Conference in New York City as follows:\n\nDate: June 4, 2026\n\nTime: 9:55 AM – 10:25 AM EDT\n\nA live webcast of the presentation may be accessed on the Investors section of\nthe Turn Therapeutics website at\nhttps://ir.turntherapeutics.com/news-events/presentations\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fir.turntherapeutics.com%2Fnews-events%2Fpresentations&esheet=54538125&newsitemid=20260519539083&lan=en-US&anchor=https%3A%2F%2Fir.turntherapeutics.com%2Fnews-events%2Fpresentations&index=1&md5=0200dc9e4d7d98bc973805b3993c59ca)\n. A replay of the webcast will be available on the Turn Therapeutics website\nfor approximately six months following the presentation.\n\nAbout Turn Therapeutics\n\nTurn Therapeutics is a biotechnology company focused on developing innovative,\nprecision therapies that target the underlying causes of inflammatory diseases\nwith high unmet needs. Its lead investigational therapy, GX-03, is a\nfirst-in-class, non-systemic topical inhibitor currently in development for\nthe treatment of moderate-to-severe atopic dermatitis. This therapy is\ndesigned to modulate key inflammatory pathways involved in eczema and other\ninflammatory dermatological conditions, specifically targeting IL-36 and\nIL-31, two cytokines that play distinct but interconnected roles in driving\nchronic skin inflammation and the itch-scratch cycle. GX-03 addresses IL-36\nupstream, where epithelial stress and barrier disruption initiate the\ninflammatory cascade, and IL-31 downstream, where itch signaling perpetuates\ndisease. It is currently being evaluated in a Phase 2 randomized controlled\ntrial, with topline results expected in mid-2026.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260519539083/en/\n(https://www.businesswire.com/news/home/20260519539083/en/)\n\nInvestor Relations / Media Contact \n\nSasha Damouni\n\nDamouni Group LLC\n\nSasha@damounigroup.com (mailto:Sasha@damounigroup.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-05-19T12:01:00.096458553Z","server_sent_at_ms":1779192060096},"received_at":"2026-05-19T12:01:00.152Z","source_url":"https://www.businesswire.com/news/home/20260519539083/en/"},"analysis":{"id":"28566","press_release_id":"39125","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Turn Therapeutics announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026.\n\nThe presentation is scheduled for 9:55 AM – 10:25 AM EDT in New York City and will be available via live webcast on the company's investor relations website.\n\nThe release reiterates that the company's lead asset, GX-03, is in a Phase 2 trial for atopic dermatitis with topline results expected in mid-2026, but provides no new data or updates.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance; no new catalyst."},"keyFigures":{},"quotedText":"Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City","namedEntities":{"people":[{"name":"Bradley Burnam","role":"CEO"},{"name":"Sasha Damouni","role":"Investor Relations Contact"}],"products":["GX-03"],"companies":[{"name":"Turn Therapeutics Inc.","ticker":"TTRX"},{"name":"Jefferies","relationship":"conference organizer"},{"name":"Damouni Group LLC","relationship":"IR firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference presentation announcement. No new clinical data, financial results, or strategic developments disclosed. Standard IR activity for a clinical-stage biotech."},"tickerRelevance":{"others":[],"primary":"TTRX"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_ir","sectorWeight":"biotech","householdBrandBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Turn Therapeutics announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference on June 4, 2026.\n\nThe presentation is scheduled for 9:55 AM – 10:25 AM EDT in New York City and will be available via live webcast on the company's investor relations website.\n\nThe release reiterates that the company's lead asset, GX-03, is in a Phase 2 trial for atopic dermatitis with topline results expected in mid-2026, but provides no new data or updates.","key_figures":{},"named_entities":{"people":[{"name":"Bradley Burnam","role":"CEO"},{"name":"Sasha Damouni","role":"Investor Relations Contact"}],"products":["GX-03"],"companies":[{"name":"Turn Therapeutics Inc.","ticker":"TTRX"},{"name":"Jefferies","relationship":"conference organizer"},{"name":"Damouni Group LLC","relationship":"IR firm"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-19T12:08:58.046Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_ir","sectorWeight":"biotech","householdBrandBoost":0}},"durationMs":16970,"modelName":"george-droid-qwen-72b"}}